SEARCH TERMS
Suggested Terms
(click to add to query)

Want to better focus your search?
Upgrade to a account to unlock 5 additional filters (including Entity Type), search inside of entities, and more!
Which are the top organizations worldwide?
Top 4 of 2,818 organizations by Linknovate score
Biocept
439.3 score | records 51
Trovagene Inc.
270.7 score | records 26
OncoCyte Corporation
235.5 score | records 31
Exosome Diagnostics
179.9 score | records 42
Where are the main hubs located?
What are the most relevant records?
Top 2 of 2,894 records by Linknovate score

One of the biggest obstacles to surviving cancer is the way the disease can shift its shape and form over time. Tumours are diverse and contain cells of many different types, with different genetic and epigenetic make-up. This allows cancer to adapt to changing environments, survive treatments and spread. Researchers want to combat this fundamental lethal property to improve treatment. But to study tumour evolution in this way is to chase a fast-moving target. Investigators must track the genetic shifts in cancer cells in real time by setting up prospective assays that sample and analyse tumours during therapy. In theory, it should then be possible to tailor a growing arsenal of cancer drugs to fight emerging patterns of resistance and relapse. But finding a way to do this in the least invasive way represents a formidable challenge — and one that lies beyond the reach of existing tissue biopsies. There is another way. Over the past few years, interest has grown in developing techniques to analyse cell-free DNA in the blood, such as prenatal genetic testing for fetal DNA in the mother’s bloodstream. As cancer takes hold, the blood fills with free-floating DNA released from dying tumour cells. These genetic fragments could be used to check on the evolution of the tumours they came from. And in a promising clinical study published this week by Nature (C. Abbosh et al. Nature http://dx.doi.org/10.1038/nature22364; 2017), scientists report how they have done just that. What’s more, their trial design — incorporating prospective observations of these circulating fragments of cancer DNA — is a step towards implementing tumour-evolution monitoring as a clinical tool that can dynamically inform treatment. The clinical data reported online in Nature, and in a parallel paper in the New England Journal of Medicine (M. Jamal-Hanjani et al. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1616288; 2017), describe the results from the first 100 patients enrolled in a trial called TRACERx, which aims to follow the tumour evolution of people with lung cancer who are undergoing therapy. The Nature paper describes a test to assess and compare genetic changes in tumours and in the blood. The dynamic tracking made possible by this “liquid biopsy” sequencing shows that early recurrence of the disease can be detected, and is associated with identifiable features in the circulating tumour DNA. The results of the analysis support the idea that such liquid biopsies could provide clinical benefit by simplifying procedures and allowing for more-intensive real-time monitoring. Clinical implementation requires additional long-term studies, so that the performance of this type of monitoring can be tested alongside therapy. This is starting to happen: the design of clinical cancer trials is evolving rapidly to accommodate biomarker testing, and a growing number of registered trials are in progress to prospectively monitor tumour progression in the blood. Still, some challenges remain, including the feasibility and cost of routinely applying liquid-biopsy techniques in clinical practice. Besides helping to guide clinical decisions, the information derived from close monitoring of tumours with liquid biopsies can be readily fed back to the cancer-research pipeline. Investigators can use this information to work out the mechanism behind the remarkable plasticity of tumours, and translational colleagues could then build on these insights to provide clinicians with improved cancer-killing drugs. Nature is pleased to bring to our audience this type of clinical study. Such research should not only help convert research findings into medicines, but also provide a wealth of information for basic and clinical scientists. We hope such papers will continue to foster collaboration, and to bridge the gaps between basic and clinical points of view. As they align their sights to parse DNA fragments in the blood, researchers of all types can learn more from patients about how to help them more effectively.

...

Patent
Yaya Diagnostics GmbH | Date: 2017-04-19

The present invention relates to means for and methods of collecting, enriching, and analyzing nucleic acids of interest of interest, e.g. those that are associated with the development of sepsis. These means may be used in vivo or in vitro using obtained nucleic acids of interest, e.g. for liquid biopsies. The invention can, inter alia, be used in the detection and enrichment as well as analysis of nucleic acids of interests such as those derived from pathogens or from individuals that may contain such pathogens.

...
Linknovate helps you find your next partner or supplier
"Linknovate brought us in just 2 weeks a supplier we searched for 3 months"
Thomas Lackner, Director of Open Innovation
Upload content to Linknovate to showcase your work
Join hundreds of start-ups, universities, research labs and corporations that use Linknovate to market their capabilities and connect with new clients and partners.
How does the expertise of two organizations compare?
Organizations compared on records for related keywords
What’s the commercial readiness level of this field?
Evolution of record type per year
What kind of sources are most common?
Weight of records per source
Name Score Publications Conferences Grants Patents Trademarks News Webs
439.3 10 10 10 10 10 10 10
270.7 10 10 10 10 10 10 10
235.5 10 10 10 10 10 10 10
179.9 10 10 10 10 10 10 10
167.2 10 10 10 10 10 10 10
166.3 10 10 10 10 10 10 10
154.2 10 10 10 10 10 10 10
137.3 10 10 10 10 10 10 10
132.9 10 10 10 10 10 10 10
124.1 10 10 10 10 10 10 10
119.7 10 10 10 10 10 10 10
113.7 10 10 10 10 10 10 10
100.1 10 10 10 10 10 10 10
92.0 10 10 10 10 10 10 10
84.5 10 10 10 10 10 10 10
81.1 10 10 10 10 10 10 10
80.3 10 10 10 10 10 10 10
80.2 10 10 10 10 10 10 10
73.8 10 10 10 10 10 10 10
73.3 10 10 10 10 10 10 10
70.9 10 10 10 10 10 10 10
70.3 10 10 10 10 10 10 10
69.6 10 10 10 10 10 10 10
66.4 10 10 10 10 10 10 10
63.7 10 10 10 10 10 10 10
62.2 10 10 10 10 10 10 10
61.9 10 10 10 10 10 10 10
61.5 10 10 10 10 10 10 10
61.0 10 10 10 10 10 10 10
61.0 10 10 10 10 10 10 10
59.0 10 10 10 10 10 10 10
57.1 10 10 10 10 10 10 10
56.7 10 10 10 10 10 10 10
56.4 10 10 10 10 10 10 10
56.0 10 10 10 10 10 10 10
55.8 10 10 10 10 10 10 10
55.4 10 10 10 10 10 10 10
55.1 10 10 10 10 10 10 10
53.7 10 10 10 10 10 10 10
53.6 10 10 10 10 10 10 10
53.3 10 10 10 10 10 10 10
52.5 10 10 10 10 10 10 10
51.2 10 10 10 10 10 10 10
51.1 10 10 10 10 10 10 10
50.3 10 10 10 10 10 10 10
48.8 10 10 10 10 10 10 10
48.5 10 10 10 10 10 10 10
48.4 10 10 10 10 10 10 10
47.8 10 10 10 10 10 10 10
47.6 10 10 10 10 10 10 10
46.8 10 10 10 10 10 10 10
46.2 10 10 10 10 10 10 10
46.1 10 10 10 10 10 10 10
45.1 10 10 10 10 10 10 10
43.6 10 10 10 10 10 10 10
43.0 10 10 10 10 10 10 10
42.7 10 10 10 10 10 10 10
42.4 10 10 10 10 10 10 10
41.6 10 10 10 10 10 10 10
41.1 10 10 10 10 10 10 10
University of Cambridge
40.8 11 - - 10 10 10 10
Medanta
40.5 - - - 10 10 10 10
Positive Bioscience
40.5 - - - 10 10 10 10
Genomic Health
40.0 1 - - 10 10 10 10
GeneNews
39.8 - - - 10 10 10 10
Epic Sciences, Inc.
39.5 3 - - 10 10 10 10
American Society of Clinical Oncology
39.1 1 - - 10 10 10 10
University of Michigan
38.6 17 - - 10 10 10 10
Montpellier University
38.6 18 - - 10 10 10 10
University of Louisville
38.5 7 - - 10 10 10 10
Chinese University of Hong Kong
38.0 9 - - 10 10 10 10
Thomas Jefferson University
37.8 7 - - 10 10 10 10
Cancer Research UK Research Institute
37.2 16 - - 10 10 10 10
Illumina
36.9 4 - - 10 10 10 10
Trovagene
36.3 - - - 10 10 10 10
Worcester Polytechnic Institute
35.9 4 - - 10 10 10 10
University Pierre and Marie Curie
35.0 23 - - 10 10 10 10
Molecular Diagnostics
34.8 - - - 10 10 10 10
University of Southern California
34.6 24 - - 10 10 10 10
MDNA Life science Inc.
34.0 - - - 10 10 10 10
American Cancer Society
33.9 - - - 10 10 10 10
Hoffmann-La Roche
33.2 4 - - 10 10 10 10
Cleveland Clinic
33.1 9 - - 10 10 10 10
ALK
33.0 - - - 10 10 10 10
Silicon Biosystems
32.0 - - - 10 10 10 10
Terumo BCT
31.9 - - - 10 10 10 10
Okayama University
31.4 6 - - 10 10 10 10
Boreal Genomics
31.2 1 - - 10 10 10 10
Illumina Inc.
31.0 - - - 10 10 10 10
Helomics
31.0 - - - 10 10 10 10
University of Twente
30.1 11 - 1 10 10 10 10
Science Translational Medicine
29.5 - - - 10 10 10 10
CRUK
29.5 - - - 10 10 10 10
Netherlands Cancer Institute
29.4 23 - - 10 10 10 10
BioFluidica Inc.
29.3 - - - 10 10 10 10
Zomedica
29.1 - - - 10 10 10 10
Memorial Sloan Kettering
28.9 - - - 10 10 10 10
Grand Hyatt
28.9 - - - 10 10 10 10
AUA
28.5 - - - 10 10 10 10
Precipio Diagnostics
28.3 - - - 10 10 10 10

One of the biggest obstacles to surviving cancer is the way the disease can shift its shape and form over time. Tumours are diverse and contain cells of many different types, with different genetic and epigenetic make-up. This allows cancer to adapt to changing environments, survive treatments and spread. Researchers want to combat this fundamental lethal property to improve treatment. But to study tumour evolution in this way is to chase a fast-moving target. Investigators must track the genetic shifts in cancer cells in real time by setting up prospective assays that sample and analyse tumours during therapy. In theory, it should then be possible to tailor a growing arsenal of cancer drugs to fight emerging patterns of resistance and relapse. But finding a way to do this in the least invasive way represents a formidable challenge — and one that lies beyond the reach of existing tissue biopsies. There is another way. Over the past few years, interest has grown in developing techniques to analyse cell-free DNA in the blood, such as prenatal genetic testing for fetal DNA in the mother’s bloodstream. As cancer takes hold, the blood fills with free-floating DNA released from dying tumour cells. These genetic fragments could be used to check on the evolution of the tumours they came from. And in a promising clinical study published this week by Nature (C. Abbosh et al. Nature http://dx.doi.org/10.1038/nature22364; 2017), scientists report how they have done just that. What’s more, their trial design — incorporating prospective observations of these circulating fragments of cancer DNA — is a step towards implementing tumour-evolution monitoring as a clinical tool that can dynamically inform treatment. The clinical data reported online in Nature, and in a parallel paper in the New England Journal of Medicine (M. Jamal-Hanjani et al. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1616288; 2017), describe the results from the first 100 patients enrolled in a trial called TRACERx, which aims to follow the tumour evolution of people with lung cancer who are undergoing therapy. The Nature paper describes a test to assess and compare genetic changes in tumours and in the blood. The dynamic tracking made possible by this “liquid biopsy” sequencing shows that early recurrence of the disease can be detected, and is associated with identifiable features in the circulating tumour DNA. The results of the analysis support the idea that such liquid biopsies could provide clinical benefit by simplifying procedures and allowing for more-intensive real-time monitoring. Clinical implementation requires additional long-term studies, so that the performance of this type of monitoring can be tested alongside therapy. This is starting to happen: the design of clinical cancer trials is evolving rapidly to accommodate biomarker testing, and a growing number of registered trials are in progress to prospectively monitor tumour progression in the blood. Still, some challenges remain, including the feasibility and cost of routinely applying liquid-biopsy techniques in clinical practice. Besides helping to guide clinical decisions, the information derived from close monitoring of tumours with liquid biopsies can be readily fed back to the cancer-research pipeline. Investigators can use this information to work out the mechanism behind the remarkable plasticity of tumours, and translational colleagues could then build on these insights to provide clinicians with improved cancer-killing drugs. Nature is pleased to bring to our audience this type of clinical study. Such research should not only help convert research findings into medicines, but also provide a wealth of information for basic and clinical scientists. We hope such papers will continue to foster collaboration, and to bridge the gaps between basic and clinical points of view. As they align their sights to parse DNA fragments in the blood, researchers of all types can learn more from patients about how to help them more effectively.


Patent
Yaya Diagnostics GmbH | Date: 2017-04-19

The present invention relates to means for and methods of collecting, enriching, and analyzing nucleic acids of interest of interest, e.g. those that are associated with the development of sepsis. These means may be used in vivo or in vitro using obtained nucleic acids of interest, e.g. for liquid biopsies. The invention can, inter alia, be used in the detection and enrichment as well as analysis of nucleic acids of interests such as those derived from pathogens or from individuals that may contain such pathogens.


The present invention relates to methods of using cell-free DNA analysis for guiding treatment of advanced prostate cancer. In particular, liquid biopsies are collected from urine and/or plasma of patients for measuring copy number variation in cell-free DNA associated with metastatic prostate cancer. In particular, urine genomic abnormality (UGA) and plasma genomic abnormality (PGA) values are contemplated for use in predicting treatment responses in advanced prostate cancer patients and for use in making decisions related to androgen deprivation therapy (ADT) treatment outcomes in hormone sensitive stage and for starting or changing chemotherapy treatments in castrate resistant advanced cancer stage.


Patent
Medcom Advance S.A., Medcom Technology S.A. and Fundacion Of Investigacion Hm Hospitales | Date: 2017-09-06

The invention relates to an apparatus and method of detecting and quantifying the number of circulating tumour cells (CTCs) and/or tumour cells (TCs) from a liquid biopsy by using a hyperoxic environment and incubation with a fluorophore-labelled metabolic indicator (fluorophore-labelled 2-D-glucose derivative) and microfluidic chips.

Claims which contain your search:

8. A microfluidic chip selected from the group consisting of:a) a mixing chip comprising(i) at least two inlets, wherein one inlet is for introducing a liquid sample and the other inlet(s) is/are for introducing a solution comprising a fluorophore-labelled metabolic indicator saturated with oxygen or components thereof, all the inlets converging in a micromixer for the mixture and incubation of the liquid sample and the solution comprising a fluorophore-labelled metabolic indicator saturated with oxygen, and(ii) an outlet to allow the exit of the mixture to a purification chip;b) a purification chip comprising(i) an inlet for the entrance of a mixture,(ii) a main microchannel with constrictions and lateral bifurcation microchannels for the extraction of the fluorophore-labelled metabolic indicator not accumulated in cells while avoiding the removal of cells,(iii) a main microchannel outlet for the exit of cells to the detection chip, and(iv) further lateral bifurcation outlets for the exit of the extracted fluorophore-labelled metabolic indicator; andc) a detection chip comprising three inlets, a first central inlet for the entrance of cells and the second and third inlets for the entrance of a solution for cell focusing, wherein the second and third inlets are situated at opposite sides of the first central inlet, all the inlets converging into a single microchannel which is optionally widen for being used as inspection region in the detection of stained cells by fluorescence, and an outlet for the exit of the mixture of cells and the solutionor a set of microfluidic chips consisting of at least two microfluidic chips selected from a), b) and c).

1. An in vitro method for the detection of a circulating tumour cell (CTC) and/or a tumour cell (TC) in a liquid sample comprising the steps of:a) optionally, culturing the liquid sample in a cell culture medium;b) incubating the cells contained in the liquid sample or the cells obtained in step a) with a solution supplemented with a fluorophore-labelled metabolic indicator and saturated with oxygen, and during an appropriate time to allow the CTCs/TCs to accumulate the fluorophore-labelled metabolic indicator;c) removing the excess of the fluorophore-labelled metabolic indicator not accumulated in cells; andd) measuring the fluorescence of the fluorophore-stained cellswherein the detection of a fluorophore-stained cell having a fluorescence intensity superior to a control cell indicates the presence of a CTC/TC in the liquid sample.

15. Use of a fluorophore-labelled metabolic indicator for the detection and/or quantification of CTCs/TCs in a liquid sample.

14. Use of the device according to any one of claims 7 or 9 to 12, or the microfluidic chip or set of microfluidic chips according to any one of claims 8 or 9 to 12, or the kit according to claim 13 for the detection and/or quantification of CTCs/TCs in a liquid sample; or for CTCs/TCs sorting, isolating or capturing.

7. A device comprising a set of microfluidic chips for the detection of circulating tumour cells (CTCs) and/or tumour cells (TCs) in a liquid sample comprising:a) a mixing chip comprisingi. at least two inlets, wherein one inlet is for introducing the liquid sample and the other inlet(s) is/are for introducing a solution comprising a fluorophore-labelled metabolic indicator saturated with oxygen or components thereof, all the inlets converging in a micromixer for the mixture and incubation of the liquid sample and the solution comprising a fluorophore-labelled metabolic indicator saturated with oxygen, andii. an outlet to allow the exit of the mixture to the purification chip;b) a purification chip comprisingi. an inlet for the entrance of the mixture,ii. a main microchannel with constrictions and lateral bifurcation microchannels for the extraction of the fluorophore-labelled metabolic indicator not accumulated in cells while avoiding the removal of cells,iii. a main microchannel outlet for the exit of cells to the detection chip, andiv. further lateral bifurcation outlets for the exit of the extracted fluorophore-labelled metabolic indicator; andc) a detection chip comprising three inlets, a first central inlet for the entrance of cells and the second and third inlets for the entrance of a solution for cell focusing, wherein the second and third inlets are situated at opposite sides of the first central inlet, all the inlets converging into a single microchannel which is optionally widen for being used as inspection region in the detection of stained cells by fluorescence, and an outlet for the exit of the mixture of cells and the solution.


News Article | June 30, 2017
Site: www.eurekalert.org

Barcelona, Spain, 30 June 2017 - A new study, to be presented at the ESMO 19th World Congress on Gastrointestinal Cancer, shows that so-called "liquid biopsies", blood tests that detect circulating tumour DNA (ctDNA), may not only sound an early alert that a treatment's effect is diminishing, but may also help explain why -sometimes offering clues about what to do next. Why a cancer treatment is losing its effectiveness, is a question that preoccupies every patient and their doctor. But checking in on a drug's tumor-fighting progress is not easy - usually involving invasive biopsies and expensive scans. "We have shown that integrating regular liquid biopsies into our patients' routine care is feasible and easily incorportated into clinical practice," said study investigator Aparna Parikh, MD, from Massachusetts General Hospital Cancer Center, in Boston, Massachusetts. "This technology can precisely help us understand each patient's indvididual disease course and allows us to tailor care based on an understanding of their specific disease biology," she said. In fact, compared to standard tissue biopsies, which can be painful and difficult to obtain, her study showed that liquid biopsies actually provided more information less invasively. The study involved nearly 40 patients with various forms of gastro-intestinal (GI) cancers, who had initially responded to therapy but then stopped. Liquid biopsies were done when their disease began to progress and ctDNA in the blood was analysed for genetic mutations that might be making them resistant to treatment. A total of 31 patients had at least one such mutation, and among them,14 had more than one. Notably in about two thirds of patients who had traditional tissue biospies taken at the same time, the liquid biopsy picked up extra mutations that could not be seen in the tissue. "Identifying what specific mutations are responsible for treatment resistance is very important in helping clinicians choosing what treatment path a patient should try next, whether it be another drug or perhaps radiation," explained Parikh. While liquid biopsies are not yet widely used outside of the research setting, Parikh believes they are set to transform cancer treatment. "We have shown this approach is feasible across many different GI cancers," she noted. "The next step is to study how best to use this new technology in daily practice. It's important for clinicians to understand its utility as well as its limitations." Commenting on the study, ESMO spokesperson Frederica Di Nicolantonio, MD, from the Candiolo Cancer Institute and University of Torino in Italy said, "this work elegantly reports that the use of clinical liquid biopsy panels can effectively identify multiple heterogeneous and co-occuring mechanisms of acquired drug resistance, all in a non-invasive manner. Clinicians should be able to better individualise patient care based on results from this technology." 1. Abstract O-001 - 'Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients' will be presented by Dr Aparna Parikh during 'Session X: Presentation of Selected Abstracts - Colorectal Cancer' on Friday, 30 June, 08:40 to 09:45 (CEST) in Auditorium B. This press release contains information provided by the authors of the highlighted abstracts and reflects the content of those abstracts. It does not necessarily reflect the views or opinions of ESMO who cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct. The ESMO World Congress on Gastrointestinal Cancer is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours. ESMO is the leading professional organisation for medical oncology. With more than 15,000 members representing oncology professionals from over 130 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment. Imedex is an industry leader in providing accredited, independent continuing medical education to health care professionals. We develop high quality scientific programming that translates the latest research into clinically relevant information. The activities have exceptional organization and outstanding educational value, with a proven sustained impact on disease management. Our programs focus on improving patient care around the world. With over 50,000 e-learning experiences annually and more than 100,000 live meeting attendees, since 2001, Imedex truly educates the global healthcare community. At Imedex, education is the best medicine®.


News Article | July 13, 2017
Site: www.prnewswire.com

LONDON, July 12, 2017 /PRNewswire/ -- Report Details Liquid Biopsies – our new study reveals trends, R&D progress, and predicted revenues Where is the liquid biopsy market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there. Download the full report: https://www.reportbuyer.com/product/4753862/ Discover How to Stay Ahead Our 205-page report provides 190 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing liquid biopsy market. See how to exploit the opportunities. Forecasts to 2027 and other analyses reveal the commercial prospects - In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares. - You find original analyses, with business outlooks and developments. - Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments. Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, you find revenue forecasts for 4 different segmentations of the market, including forecasts for 3 sample types, 3 biomarker types, 7 applications and 4 end users: - Liquid biopsy Market Forecasts to 2027, By Sample Type - Blood - Urine - Other - Liquid biopsy Technologies Market Forecasts to 2027, By Biomarker Type - CTC - ctDNA - Exosomes - Liquid biopsy Technologies Market Forecasts to 2027, By Application - Lung Cancer - Gastrointestinal Cancer - Breast Cancer - Colorectal Cancer - Leukaemia - Prostate Cancer - Other Cancers - Liquid biopsy Technologies Market Forecasts to 2027, By End User - Hospitals - Academic Institutes - Diagnostic Laboratories - Cancer Research Centres In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts 5 leading regional markets and 19 leading national markets: - North America - US - Canada - Europe - Germany - France - UK - Italy - Spain - Russia - Rest of Europe - APAC - Japan - China - India - South Korea - Singapore - Australia & New Zealand - Rest of APAC - Latin America - Brazil - Argentina - Rest of Latin America - MEA - GCC - South Africa - Rest of MEA There will be growth in both established and in developing countries. Our analyses show that the developing markets, China and India in particular, will continue to achieve high revenue growth to 2027. Developments worldwide in medical device regulation, especially in the US and Japan will influence the market. Leading companies and the potential for market growth Overall world revenue for liquid biopsy will surpass $0.4bn in 2017, our work calculates. We predict strong revenue growth through to 2027. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. How the Liquid biopsy Technologies Market report helps you In summary, our 204-page report provides you with the following knowledge: - Revenue forecasts to 2027 for the world liquid biopsy market and 4 different segmentations, with 3 sample types, 3 biomarker types, 7 applications and 4 end-user types – discover the industry's prospects, finding the most lucrative places for investments and revenues - Revenue forecasts to 2027 for the leading 5 regional and 19 national markets – North America (US, Canada), Latin America (Brazil, Argentina, Rest of Latin America), Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), APAC (Japan, China, India, South Korea, Singapore, Australia & New Zealand and Rest of APAC), MEA (GCC, South Africa and Rest of MEA) - Discussion of what stimulates and restrains companies and the market - Prospects for established firms and those seeking to enter the market Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight. Download the full report: https://www.reportbuyer.com/product/4753862/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com


Patent
Epic Sciences, Inc. | Date: 2017-08-23

The disclosure provides a method for determining if a subject afflicted with cancer is a candidate for Programmed Death Ligand-1 (PD-Ll) targeted immunotherapy, which method comprises (a) providing a liquid biopsy sample obtained from the subject afflicted with cancer; (b) detecting CTCs in the liquid biopsy sample; (c) calculating what proportion of CTCs in the liquid biopsy express PD-Ll; and (c) identifying the subject as a candidate for PD-Ll targeted immunotherapy based on an assessment that the proportion of the CTCs in the liquid biopsy that express PD-Ll exceeds a pre-determined threshold level.

Claims which contain your search:

1. A method for determining if a subject afflicted with cancer is a candidate for Programmed Death Ligand-1 (PD-Ll) targeted immunotherapy, which method comprises (a) providing a liquid biopsy sample obtained from the subject afflicted with cancer; (b) detecting CTCs in the liquid biopsy sample; (c) calculating what proportion of CTCs in the liquid biopsy express PD-Ll; and (c) identifying the subject as a candidate for PD-Ll targeted immunotherapy based on an assessment that the proportion of the CTCs in the liquid biopsy that express PD-Ll exceeds a pre-determined threshold level.

4. The method of claim 1, further comprising identification of white blood cells (WBCs) in the liquid biopsy sample.

6. The method of claim 5, further comprising enumeration of WBCs in the liquid biopsy sample.

12. The method of claim 9, comprising communicating that the subject was not identified as a candidate based on the assessment that the proportion of CTCs in the liquid biopsy that express PD-Ll is below a predetermined threshold level.

16. A method of monitoring expression of PD-Ll on circulating tumor cells (CTCs) of a subject undergoing PD-Ll targeted immunotherapy, which method comprises (a) providing at least two liquid biopsy samples from the subject undergoing PD-Ll targeted immunotherapy, wherein the samples were obtained at separate pre-determined time points; (b) detecting CTCs in the liquid biopsy samples; (c) calculating what proportion of CTCs in the liquid biopsy samples express PD-Ll; and (c) comparing the proportion of CTCs that express PD-Ll between the liquid biopsy samples to monitor the expression of PD-Ll .

20. A method for determining whether a determining if a subject afflicted with cancer is at risk for metastasis, which method comprises (a) providing a liquid biopsy obtained from the subject afflicted with cancer; (b) detecting CTCs that express PDL-1 in the liquid biopsy sample; (c) calculating what proportion of CTCs in the liquid biopsy express PD-Ll are CK-negative; and (c) identifying the subject as a candidate at risk for metastasis based on an assessment that the proportion of CK-negative CTCs in the liquid biopsy that express PD-Ll exceeds a predetermined threshold level.


News Article | August 15, 2017
Site: www.prnewswire.com

NEW YORK, Aug. 14, 2017 /PRNewswire/ -- This report covers the market for liquid biopsy, including cfDNA, CTC and other technologies. The market data in this report is segmented by those technologies type of cancer tested and by purpose - testing, screening, drug monitoring. Companies are profiled and the top ten companies are ranked and their recent activities detailed.


DUBLIN--(BUSINESS WIRE)--The "Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA), Product (Instruments, Assay Kits), End User (Reference Laboratory) - Global Forecast to 2022" report has been added to Research and Markets' offering. The global liquid biopsy market is projected to reach USD 2,047.9 Million by 2022 from USD 715.7 Million in 2017, at a CAGR of 23.4%. Factors such as increasing prevalence of cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancements to augment market revenues, rising emphasis on personalized medicine in clinical practice, and increased funding for liquid biopsy R&D are driving the growth of the market. The number of companies offering liquid biopsy devices is increasing, globally. Major market players are focusing on strengthening their product offerings, mergers and acquisitions, and geographic presence by entering into contracts and agreements with other established players in the market. For instance, in January 2017, Bio-Rad Laboratories, Inc. (US) entered into a definitive agreement with RainDance Technologies, Inc. (US) to acquire the latter. The acquisition will result in Bio-Rad's expansion into next-generation sequencing applications. The report analyzes the liquid biopsy market by product, circulating biomarker, clinical application, application, end user, and region. On the basis of product and service, the market is segmented into assay kits, instruments, and services. The assay kits segment is expected to account for the largest share of the global market in 2017. Factors such as the increasing demand for liquid biopsy tests, increasing applications of liquid biopsies, and the need for reliable and specific assays are expected to drive the market in the coming years. For more information about this report visit https://www.researchandmarkets.com/research/gxnl8z/liquid_biopsy


News Article | September 25, 2017
Site: www.prnewswire.co.uk

According to a new market research report " Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA), Product (Instruments, Assay Kits), End User (Reference Laboratory) - Global Forecast to 2022", published by MarketsandMarkets™, the market is expected to reach USD 2,047.9 Million by 2022 from an estimated USD 715.7 Million in 2017, at a CAGR of 23.4%. The key factors driving the growth of this market include increasing prevalence of cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D. Browse 133 Market Data Tables and 44 Figures spread through 204 Pages and in-depth TOC on " Liquid Biopsy Market" Early buyers will receive 10% customization on this report By product, the assay kits segment is expected to account for the largest share of the market in 2017 On the basis of product, the Liquid Biopsy Market is broadly segmented into assays kits, instruments, and services. In 2017, the assay kits segment is expected to account for the largest share of this market. The increase in basic research and commercial applications of liquid biopsy, increase in demand for liquid biopsy tests, and the need for reliable and specific assays are expected to drive the market growth. By circulating biomarkers, circulating tumor cells is expected to account for the largest market share in 2017 Based on circulating biomarkers the market is categorized into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. In 2017, the circulating tumor cells segment is expected to account for the largest share of the Liquid Biopsy Market. The ability for early assessment of patient prognosis and also providing valuable information to make a clinical decision is driving the growth of the CTC segment in the Liquid Biopsy Market. By clinical application, the therapy selection segment is expected to account for the largest market share in 2017 Based on clinical application, the Liquid Biopsy Market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. The therapy selection segment is expected to account for the largest share of the Liquid Biopsy Market in 2017. This is due to the ability of therapy selection to detect advanced-stage cancers (stage III and IV), followed by increasing studies on liquid biopsy and advancements made in this field to also aid in detection of early-stage cancers. By application, the cancer segment is expected to account for the largest market share in 2017 Based on application, the Liquid Biopsy Market is segmented into cancer and non-cancer applications (which includes reproductive health and organ transplant diagnostics). In 2017, cancer applications segment is expected to account for the largest share of the Liquid Biopsy Market. Increasing prevalence of cancer and the growing number of research studies on liquid biopsy for cancer applications is driving the growth of this market. By end user, the reference laboratories segment is expected to account for the largest market share in 2017 Based on end user, the Liquid Biopsy Market is segmented into reference laboratories, hospitals and physician laboratories, academic and research centers, and other end users (public health laboratories, pathology laboratories, and small molecular laboratories). Reference laboratories form the largest and fastest-growing end-user segment of the Liquid Biopsy Market. The large share of this segment is attributed to the increasing volume of liquid biopsy test samples outsourced to reference laboratories. North America is expected to dominate the market in 2017 North America is expected to account for the largest share of the Liquid Biopsy Market in 2017, followed by Europe. A number of factors such as the easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals, rising prevalence of cancer in the US and Canada, technological advancements in liquid biopsy products, and growing public and private funding to support research activities in the field of liquid biopsy are aiding market growth in the region. The key players in the global Liquid Biopsy Market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US). BIOPSY DEVICES MARKET by Product (Core Needle Biopsy , Aspiration Biopsy , Vacuum Assisted Biopsy ) Application (Breast Biopsy , Lung Biopsy , Prostate Biopsy ) Guidance (Stereotactic, Ultrasound) & by End User (Hospital) - Global Forecast to 2022 BREAST BIOPSY MARKET by Product (Table, Needle, Localization wire, Guidance System), Type (Open Biopsy - Excisional, Incisional, Needle- Core Needle Aspiration, Vacuum Assisted) & by Guidance system (Ultrasound, Stereotactic, MRI) - Forecast to 2020 MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets